Aster
Aster
Everything around us is becoming measurable in real time, except life itself. The molecules that govern our bodies and our environment, from hormones to pathogens, are still read as snapshots, not in real time. Aster is building the continuous biosensing layer that brings living systems online.
Our most powerful systems run on continuous, precise data: trading terminals price markets by the millisecond, search engines rank the world from a constant stream of signals. Biology has no such feed. The chemistry that governs health, fertility, stress and exposure is sampled once and extrapolated for months, even though the decisive information lives in a signal's timing, slope and persistence, exactly what a single measurement discards.
This matters because the cell is the most sophisticated sensor we know of: it detects single molecules, performs its own signal processing, and responds in real time, in a volume a fraction the width of a hair. Yet we study it almost entirely open-loop, perturb, wait minutes to days, then lyse and sequence the endpoint. We characterise the most advanced molecular machines in the universe largely from the autopsy.
Engineered systems succeed because they run closed-loop. A self-driving car continuously senses, acts, and senses again, correcting many times a second. Cell biology is still run open-loop: we intervene, wait minutes to days, then read a single endpoint and infer what happened, the difference between steering continuously and setting a course, closing your eyes, and checking the result only at the destination. Closing the loop in biology demands a continuous, high-bandwidth readout of the system while it runs, paired with the ability to act and observe the response in real time. That is the gap, and the foundation for everything from early disease detection to biosecurity.
Sensors stream temperature, motion, location and power around the clock. Continuous, cheap, ubiquitous.
Continuous glucose monitoring transformed diabetes care: proof that a continuous molecular signal changes medicine.
Hormones, metabolites, pathogens, drug levels: the rest of the body's chemistry has no continuous readout.
We're building technology that reads the chemistry of living systems continuously, turning signals that today are captured once into a live, real-time stream.
Aster is a pre-incorporation venture run across leading European research labs. We are building the first proofs of the platform, and our research is advanced through competitive, non-dilutive grants rather than an open equity round. We are still operating largely in stealth, but we are open by instinct: we share as much as we can with collaborators, and we welcome conversations with potential partners and investors who believe in the mission.
We're talking with a small number of scientists, partners and long-term investors who share the thesis. We're not in a hurry to raise, we are in a hurry to build.
Where we build
Supported by
